Pharmaceutical Care Management Association Issues Statement on Trump Administration’s Proposed Medicare Part B Pricing Model

WASHINGTON, Oct. 25 -- The Pharmaceutical Care Management Association issued the following statement by President and CEO JC Scott on the Trump Administration's proposed Medicare Part B pricing model:

"We are encouraged the Administration is exploring greater use of competitive pharmacy benefit manager (PBM) tools in Medicare Part B to ensure beneficiaries have access to medications that may otherwise not be affordable. Some of the highest priced drugs are found in Medicare Part B, where PBMs currently do not play any meaningful role. Promoting fair competition is the key to reducing costs for the program and Medicare beneficiaries.

We look forward to reviewing the proposal, and working with the Administration and Congress to explore additional ways to leverage proven private-sector PBM negotiating tools."